Advice and Guidance for Pharmaceutical Serialisation Strategy Development
(Pt2) Avoiding the Supply Risk From Serialisation With CMOsBe4ward
This WP is the second in a two-part whitepaper: 'Avoiding the Supply Risk From Serialisation With CMOs'. Download this free whitepaper to find out more about serialisation, including making sure you have backup plans, ensuring you have a cross-functional team, and not relying on software vendors.
Serialisation legislation in the US, the EU, and many other countries means that without the successful and timely implementation and integration of CMO serialisation capabilities, pharmaceutical companies will no longer be able to supply products. The complex, evolving, immature, and increasingly resource-constrained area of serialisation means that the risks of significant supply interruptions are high.